ClinicalTrials.gg
RecruitingNCT06930976TORCHUpdated Nov 19, 2026

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

An interventional study of 13C6-Glucose in Glucose, Metabolism and Isotope Labeling, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

02

Conditions studied

  • Glucose
  • Metabolism
  • Isotope Labeling
  • Immune System and Related Disorders
03

In context

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 or older

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Prisoner or in police custody
  • Uncontrolled hyperglycemia/diabetes
  • Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
  • Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
  • Any reason which, in the opinion of the study investigator, adds additional risk to the participant
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    13C6-Glucose

    10-25gm of 13C6-Glucose

    Drug: 13C6-Glucose

Interventions

  • Drug13C6-Glucose

    Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion

06

What researchers measure

Primary outcomes

  1. 13C6-glucose uptake in immune cells

    Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.

    Time frame: Up to 4 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported will be made available after de-identification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: The data will become available within 6 months of publication of the outcomes and will remain available for at least 5 years.

Access criteria: Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Principle Investigator and relevant institutional review boards.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2025
First posted
Apr 16, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06930976
Responsible party
Matthew Stier (Assistant Professor of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Apr 16, 2025
Start date
Oct 1, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Matthew T Stier, M.D., Ph.D.
Contact
matthew.stier@vumc.org
615-875-4978
Matthew T Stier, M.D., Ph.D.
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion